[{"id":"1f16af08-2617-4040-87e8-26981325edcc","acronym":"","url":"https://clinicaltrials.gov/study/NCT02344810","created_at":"2021-01-18T11:09:02.428Z","updated_at":"2024-07-02T16:35:47.151Z","phase":"Phase 2","brief_title":"C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer","source_id_and_acronym":"NCT02344810","lead_sponsor":"Eastern Cooperative Oncology Group","biomarkers":" HER-2 • MET","pipe":" | ","alterations":" HER-2 negative • MET amplification • MET expression","tags":["HER-2 • MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • MET amplification • MET expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • oxaliplatin • leucovorin calcium • AMG 337"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 03/06/2015","start_date":" 03/06/2015","primary_txt":" Primary completion: 03/06/2015","primary_completion_date":" 03/06/2015","study_txt":"","study_completion_date":"","last_update_posted":"2023-05-25"},{"id":"fe1edbe0-a8fb-4185-a3ef-fdb9df88b4de","acronym":"","url":"https://clinicaltrials.gov/study/NCT02096666","created_at":"2021-01-18T09:40:46.108Z","updated_at":"2024-07-02T16:36:19.082Z","phase":"Phase 1/2","brief_title":"A Phase 1/2 Study Evaluating AMG 337 in Asian Subjects","source_id_and_acronym":"NCT02096666","lead_sponsor":"Amgen","biomarkers":" MET","pipe":" | ","alterations":" MET amplification","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AMG 337"],"overall_status":"Completed","enrollment":" Enrollment 11","initiation":"Initiation: 04/15/2014","start_date":" 04/15/2014","primary_txt":" Primary completion: 11/05/2015","primary_completion_date":" 11/05/2015","study_txt":" Completion: 12/07/2018","study_completion_date":" 12/07/2018","last_update_posted":"2021-12-28"},{"id":"faffdd28-d29f-488c-a19b-3cd50c82dd51","acronym":"","url":"https://clinicaltrials.gov/study/NCT03147976","created_at":"2021-01-27T18:55:48.199Z","updated_at":"2024-07-02T16:36:56.317Z","phase":"Phase 2","brief_title":"QUILT-3.036: AMG 337 in Subjects With Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT03147976","lead_sponsor":"NantPharma, LLC","biomarkers":" MET","pipe":" | ","alterations":" MET exon 14 mutation • MET overexpression • MET mutation","tags":["MET"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MET exon 14 mutation • MET overexpression • MET mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e AMG 337"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 05/02/2018","start_date":" 05/02/2018","primary_txt":" Primary completion: 08/23/2019","primary_completion_date":" 08/23/2019","study_txt":" Completion: 08/23/2019","study_completion_date":" 08/23/2019","last_update_posted":"2019-08-28"}]